Company / Depreciation & Amortization
Amphstar Pharmaceuticals, Inc. Depreciation & Amortization History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$25.7M
FY2023
5-year range
$10.2M / $25.7M
FY2019-FY2023
Trend
+104.3%
vs FY2022
Sector context
#41 of 168
Health Care
What the data says
Amphstar Pharmaceuticals, Inc.'s depreciation & amortization of $26M is higher than 76% of companies in the Health Care sector (FY2023). Depreciation & Amortization has increased for 5 consecutive years, from $6M in FY2018 to $26M in FY2023.
Based on SEC 10-K filings.
$26M in FY2023 with a 5-year CAGR of +33.6%. Top quartile in the Health Care sector.
Increased from $10M to $26M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +41.8%
- 5-Year CAGR
- +33.6%
- 10-Year CAGR
- -
Sector benchmark
-87.9% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s depreciation & amortization has grown for 5 consecutive years.
- 5-year CAGR of +33.6%, indicating consistent growth.
- In FY2023, depreciation & amortization increased 104.3% year-over-year.
- Ranks #41 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $25.7M | +104.3% |
| FY2022 | $12.6M | +23.2% |
| FY2021 | $10.2M | +13.2% |
| FY2020 | $9.0M | +27.9% |
| FY2019 | $7.1M | +16.6% |
| FY2018 | $6.1M | -5.7% |
| FY2017 | $6.4M | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026